# Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer

## TL;DR

The study compares two treatment options for a specific type of colorectal cancer based on tumor location and genetic status.

## Contribution

The paper introduces a comparative analysis of second-line therapies for RAS/RAF wild-type, right-sided colorectal cancer.

## Key findings

- Anti-vascular endothelial growth factor therapy is evaluated against anti-epidermal growth factor receptor therapy.
- The study focuses on effectiveness in second-line treatment for a specific subset of colorectal cancer patients.

## Abstract

This comparative effectiveness study investigates anti–vascular endothelial growth factor vs anti–epidermal growth factor receptor therapy in second-line treatment among patients with RAS/RAF wild-type, right-sided cancer.